WO2002085312A3 - Process for purifying 6-methoxy omeprazole - Google Patents

Process for purifying 6-methoxy omeprazole Download PDF

Info

Publication number
WO2002085312A3
WO2002085312A3 PCT/US2002/015254 US0215254W WO02085312A3 WO 2002085312 A3 WO2002085312 A3 WO 2002085312A3 US 0215254 W US0215254 W US 0215254W WO 02085312 A3 WO02085312 A3 WO 02085312A3
Authority
WO
WIPO (PCT)
Prior art keywords
purifying
products
methoxy omeprazole
omeprazole
methoxy
Prior art date
Application number
PCT/US2002/015254
Other languages
French (fr)
Other versions
WO2002085312A2 (en
Inventor
Linda Whittal
Grayson Walker Stowell
Robert R Whittle
Original Assignee
Aaipharma Inc
Linda Whittal
Grayson Walker Stowell
Robert R Whittle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/839,449 external-priority patent/US6608091B2/en
Priority claimed from US09/839,395 external-priority patent/US6673936B2/en
Application filed by Aaipharma Inc, Linda Whittal, Grayson Walker Stowell, Robert R Whittle filed Critical Aaipharma Inc
Priority to CA002443605A priority Critical patent/CA2443605A1/en
Priority to KR10-2003-7013544A priority patent/KR20030088506A/en
Priority to HU0304004A priority patent/HUP0304004A2/en
Priority to EP02736828A priority patent/EP1379518A2/en
Priority to JP2002582888A priority patent/JP2004528331A/en
Publication of WO2002085312A2 publication Critical patent/WO2002085312A2/en
Publication of WO2002085312A3 publication Critical patent/WO2002085312A3/en
Priority to NO20034679A priority patent/NO20034679L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides processes for purifying 6-methoxy omeprazole, products using such processes, pharmaceutical formulations using such products, and methods of using such products for gastric acid inhibition.
PCT/US2002/015254 2001-04-20 2002-04-17 Process for purifying 6-methoxy omeprazole WO2002085312A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002443605A CA2443605A1 (en) 2001-04-20 2002-04-17 Process for purifying 6-methoxy omeprazole
KR10-2003-7013544A KR20030088506A (en) 2001-04-20 2002-04-17 Process for purifying 6-methoxy omeprazole
HU0304004A HUP0304004A2 (en) 2001-04-20 2002-04-17 Process for purifying 6-methoxy omeprazole and pharmaceutical composition containing the compound
EP02736828A EP1379518A2 (en) 2001-04-20 2002-04-17 Process for purifying 6-methoxy omeprazole
JP2002582888A JP2004528331A (en) 2001-04-20 2002-04-17 Method for purifying 6-methoxyomeprazole
NO20034679A NO20034679L (en) 2001-04-20 2003-10-20 Process of purifying 6-methoxyomeprazole

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/839,449 US6608091B2 (en) 2001-04-20 2001-04-20 Process for purifying 6-methoxy omeprazole
US09/839,449 2001-04-20
US09/839,395 2001-04-20
US09/839,395 US6673936B2 (en) 2001-04-20 2001-04-20 Process for purifying 6-methoxy omeprazole

Publications (2)

Publication Number Publication Date
WO2002085312A2 WO2002085312A2 (en) 2002-10-31
WO2002085312A3 true WO2002085312A3 (en) 2003-04-03

Family

ID=27126104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/015254 WO2002085312A2 (en) 2001-04-20 2002-04-17 Process for purifying 6-methoxy omeprazole

Country Status (8)

Country Link
EP (1) EP1379518A2 (en)
JP (1) JP2004528331A (en)
KR (1) KR20030088506A (en)
CN (1) CN100503596C (en)
CA (1) CA2443605A1 (en)
HU (1) HUP0304004A2 (en)
NO (1) NO20034679L (en)
WO (1) WO2002085312A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204215A1 (en) * 1985-05-24 1986-12-10 G.D. Searle & Co. 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382838A1 (en) * 1999-08-26 2001-03-01 Frederick D. Sancilio Ft-raman spectroscopic measurement of omeprazole isomer ratio in a composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204215A1 (en) * 1985-05-24 1986-12-10 G.D. Searle & Co. 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines

Also Published As

Publication number Publication date
WO2002085312A2 (en) 2002-10-31
CA2443605A1 (en) 2002-10-31
NO20034679D0 (en) 2003-10-20
HUP0304004A2 (en) 2004-04-28
KR20030088506A (en) 2003-11-19
EP1379518A2 (en) 2004-01-14
JP2004528331A (en) 2004-09-16
CN1503791A (en) 2004-06-09
CN100503596C (en) 2009-06-24
NO20034679L (en) 2003-10-20

Similar Documents

Publication Publication Date Title
IL161431A0 (en) beta-PHENYL-alpha-OXYSUBSTITUTED PROPIONIC ACID DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MXPA03006303A (en) Apparatus and method for providing point of purchase products.
WO2005046603A3 (en) Pyridine compounds
MXPA03007983A (en) Process for the preparation of middle distillates.
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AU2002229784A1 (en) Method for obtaining purified hydroxytyrosol from products and by-products derived from the olive tree
MXPA03007087A (en) Process for the manufacture of phenylacetic acid derivatives.
MXPA03007635A (en) P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same.
HK1064261A1 (en) Method for the treatment of tobacco.
AU2001285747A1 (en) Method for the treatment of tobacco
WO2003037863A3 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
ZA200309514B (en) Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives.
WO2002024695A3 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
NO20033318L (en) 2H-1-benzopyran derivatives, process of manufacture, and pharmaceutical compositions thereof
AU2002309083A1 (en) Method for identifying drugs for the treatment of type ii diabetes
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
IL157709A0 (en) Process for the preparation of 1,2-benzisoxazole-3-acetic acid
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
WO2002085312A3 (en) Process for purifying 6-methoxy omeprazole
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
MXPA02003042A (en) Process for preventing formation of scale.
WO2004055001A3 (en) Rabeprazole calcium
ZA200101058B (en) Process for the treatment of gases.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002736828

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002309805

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2443605

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: P20030828A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 1020037013544

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 028084594

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002582888

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002736828

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002736828

Country of ref document: EP